tuberculosis vaccines

Summary

Summary: Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.

Top Publications

  1. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals
    Clare R Sander
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK
    Am J Respir Crit Care Med 179:724-33. 2009
  2. pmc Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
  3. doi A multistage tuberculosis vaccine that confers efficient protection before and after exposure
    Claus Aagaard
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Nat Med 17:189-94. 2011
  4. ncbi IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge
    Shabaana A Khader
    Trudeau Institute, Saranac Lake, New York 12983, USA
    Nat Immunol 8:369-77. 2007
  5. pmc Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis
    H Martin Vordermeier
    TB Research Group, VLA Weybridge, New Haw, Addlestone, Surrey, United Kingdom
    Infect Immun 77:3364-73. 2009
  6. doi New vaccines for tuberculosis
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Lancet 375:2110-9. 2010
  7. doi Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells
    Thomas Lindenstrøm
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    J Immunol 182:8047-55. 2009
  8. pmc Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
    Laith J Abu-Raddad
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 106:13980-5. 2009
  9. doi Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    J Infect Dis 203:1832-43. 2011
  10. pmc Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation
    Kerstin Werninghaus
    Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, D 81675 Munich, Germany
    J Exp Med 206:89-97. 2009

Research Grants

Detail Information

Publications268 found, 100 shown here

  1. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals
    Clare R Sander
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK
    Am J Respir Crit Care Med 179:724-33. 2009
    ..An effective new tuberculosis (TB) vaccine regimen must be safe in individuals with latent TB infection (LTBI) and is a priority for global health care...
  2. pmc Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
    ..This includes induction of novel Th1-cell populations that have not been previously described in humans...
  3. doi A multistage tuberculosis vaccine that confers efficient protection before and after exposure
    Claus Aagaard
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Nat Med 17:189-94. 2011
    All tuberculosis vaccines currently in clinical trials are designed as prophylactic vaccines based on early expressed antigens...
  4. ncbi IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge
    Shabaana A Khader
    Trudeau Institute, Saranac Lake, New York 12983, USA
    Nat Immunol 8:369-77. 2007
    ....
  5. pmc Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis
    H Martin Vordermeier
    TB Research Group, VLA Weybridge, New Haw, Addlestone, Surrey, United Kingdom
    Infect Immun 77:3364-73. 2009
    ..These findings also have implications for human tuberculosis vaccine development...
  6. doi New vaccines for tuberculosis
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Lancet 375:2110-9. 2010
    ..Long-term vaccination strategies need to target these more ambitious goals. Even though vaccine development will have a price, the return of investment will greatly exceed original costs...
  7. doi Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells
    Thomas Lindenstrøm
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    J Immunol 182:8047-55. 2009
    ....
  8. pmc Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
    Laith J Abu-Raddad
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 106:13980-5. 2009
    ..Elimination will require new delivery strategies, such as mass vaccination campaigns, and new products targeted at latently infected people...
  9. doi Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    J Infect Dis 203:1832-43. 2011
    ..We assessed the safety of and characterized the T cell response induced by 3 doses of the candidate vaccine, MVA85A, in BCG-vaccinated infants from a setting where tuberculosis is endemic...
  10. pmc Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation
    Kerstin Werninghaus
    Institute of Medical Microbiology, Immunology and Hygiene, Technical University Munich, D 81675 Munich, Germany
    J Exp Med 206:89-97. 2009
    ..These data provide a molecular basis for the immunostimulatory activity of TDB and TDM and identify the Syk-Card9 pathway as a rational target for vaccine development against tuberculosis...
  11. pmc Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
    ..This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis...
  12. ncbi Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis
    Jun Wang
    Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Centre for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    J Immunol 173:6357-65. 2004
    ..Our study also lends strong evidence that respiratory mucosal vaccination is critically advantageous over systemic routes of vaccination against TB...
  13. pmc Tuberculosis vaccines in clinical trials
    Rosalind Rowland
    The Jenner Institute, Old Road Campus Research Building, Oxford University, Oxford, OX3 7DQ, UK
    Expert Rev Vaccines 10:645-58. 2011
    ..There is a great need for validated animal models, identification of immunological biomarkers of protection and field sites with the capacity for large-scale efficacy testing in order to develop and license a novel TB vaccine or regimen...
  14. ncbi Airway delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: role of proinflammatory signals in the lung
    Mangalakumari Jeyanathan
    Centre for Gene Therapeutics, M G DeGroote Institute for Infectious Disease Research, and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    J Immunol 181:5618-26. 2008
    ..Our study holds implication for the future design of DNA vaccination strategies against intracellular infections...
  15. ncbi Recent findings in immunology give tuberculosis vaccines a new boost
    Stefan H E Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Schumannstrasse 21 22, 10117 Berlin, Germany
    Trends Immunol 26:660-7. 2005
    ..For clinical trials, biomarkers need to be defined with T cells alternating between lung and periphery as prime indicator cells...
  16. doi Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production
    Daniel Elias
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    Vaccine 26:3897-902. 2008
    ..14). The data presented here demonstrate that chronic worm infection reduces the immunogenicity of BCG in humans and this was associated with increased TGF-beta production but not with enhanced Th2 immune response...
  17. doi Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen
    Yasir A W Skeiky
    Aeras Global TB Vaccine Foundation, Rockville, MD 20850, USA
    Vaccine 28:1084-93. 2010
    ..Therefore, all non-clinical data supports the suitability of HyVac4 as a safe, immunogenic, and effective vaccination in a prime-boost regimen with BCG...
  18. doi Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 29:2902-9. 2011
    ..These data support efforts to use MFT cell analyses as a measure of TB vaccine immunogenicity in human immunization studies...
  19. pmc The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults
    Brian Abel
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, UCT Health Sciences, Anzio Road, Observatory 7925, Cape Town, South Africa
    Am J Respir Crit Care Med 181:1407-17. 2010
    ..AERAS-402 is a novel tuberculosis vaccine designed to boost immunity primed by bacillus Calmette-Guérin (BCG), the only licensed vaccine...
  20. pmc Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa
    Roger H Brookes
    Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia
    PLoS ONE 3:e2921. 2008
    ..We assessed the safety and immunogenicity of this new vaccine in West African volunteers...
  21. doi Tuberculosis vaccine research: the impact of immunology
    Lewellys F Barker
    Aeras Global TB Vaccine Foundation, Rockville, MD 20850, USA
    Curr Opin Immunol 21:331-8. 2009
    ....
  22. ncbi Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization
    Zhou Xing
    Infectious Diseases Division, Centre for Gene Therapeutics and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ont, Canada
    Tuberculosis (Edinb) 86:211-7. 2006
    ..We have also recently developed a recombinant vesicular stomatitis virus-vectored (VSV) TB vaccine. Ad and VSV vector systems will be complementary to each other for BCG prime-virus vaccine boost immunization protocols...
  23. pmc A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 185:769-78. 2012
    ..Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control...
  24. doi Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection
    Fangliu Yu
    Department of Pathogenic Biology and Immunology, Medical School, Southeast University, Nanjing, China
    Nanomedicine 8:1337-44. 2012
    ..tuberculosis in the mice. These findings highlighted the potential utility of Fe3O4-Glu-polyethyleneimine nanoparticles encapsulated with the DNA vaccine as a prophylactic vaccine in the M. tuberculosis-infected mouse model...
  25. pmc Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity
    Simone A Joosten
    Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
    PLoS Pathog 6:e1000782. 2010
    ..Our results significantly increase our understanding of the human immune response to Mtb by identification of CD8(+) T-cell responses to novel HLA-E binding peptides of Mtb, which have cytotoxic as well as immunoregulatory activity...
  26. ncbi Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity
    Marcus A Horwitz
    Department of Medicine, CHS 37 121, School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1688, USA
    Vaccine 24:443-51. 2006
    ..This study demonstrates that a very low inoculum of rBCG30 organisms has the capacity to induce strong protective immunity against tuberculosis and that rBCG30 is an extremely potent delivery system for mycobacterial antigens...
  27. ncbi Towards new tuberculosis vaccines
    Stefan Svenson
    Department of Clinical Research and Education, South Hospital, Karolinska Institutet, Stockholm, Sweden
    Hum Vaccin 6:309-17. 2010
    ..The live attenuated Bacillus Calmette-Guérin (BCG) vaccine which is the only currently available TB vaccine does not confer any significant protection against the most common and contagious form of TB-adult pulmonary TB...
  28. ncbi Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?
    Graham A W Rook
    Centre for Infectious Disease and International Health, University College London, Windeyer Institute of Medical Sciences, London W1T 4JF, UK
    Vaccine 23:2115-20. 2005
    ..A successful vaccine, rather than driving a Th1 response, might need to suppress this pre-existing subversive Th2-like component...
  29. pmc Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
    Katarina Radosevic
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 75:4105-15. 2007
    ..These results unify conflicting reports on the relative importance of CD4 versus CD8 T-cell responses in protection and emphasize the key role of IFN-gamma...
  30. pmc Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Clin Vaccine Immunol 17:1066-73. 2010
    ..These data highlight the intricate balance of effector and regulatory immune responses induced by vaccination and that preexisting immunity to mycobacterial antigens may affect the composition of vaccine-induced T-cell subsets...
  31. doi Novel prophylactic and therapeutic vaccine against tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 27:3267-70. 2009
    ..These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical trials...
  32. ncbi Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis
    Beston Hamasur
    Swedish Institute for Infectious Disease Control, S 17182 Solna, Sweden
    Vaccine 21:4081-93. 2003
    ..In guinea-pigs, immunization with AMOs-Ag85B in Eurocine L3 adjuvant followed by aerogenic challenge with M. tuberculosis H37Rv resulted in increased survival and reduced pathology in lungs and spleens relative to non-immunized animals...
  33. pmc Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis
    Liana Tsenova
    Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    Infect Immun 74:2392-401. 2006
    ..Interestingly, Mtb72F+AS01B induced better protection against leukocytosis and weight loss, suggesting that the polyprotein in this adjuvant may boost immunity without exacerbating inflammation in previously BCG-vaccinated individuals...
  34. ncbi A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis
    Vasan K Sambandamurthy
    Howard Hughes Medical Institute and Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA
    Nat Med 8:1171-4. 2002
    ..Our findings highlight the importance of de novo pantothenate biosynthesis in limiting the intracellular survival and pathogenesis of M. tuberculosis without reducing its immunogenicity in vaccinated mice...
  35. pmc Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates
    Michelle H Larsen
    Albert Einstein College of Medicine, Bronx, NY 1461, USA
    Vaccine 27:4709-17. 2009
    ..BCG vaccinates had reduced tuberculosis-associated pathology and improved clinical scores as compared to saline and mc(2)6030 vaccinates, but survival did not differ among the groups...
  36. doi Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment
    Mangalakumari Jeyanathan
    Centre for Gene Therapeutics, M G DeGroote Institute for Infectious Disease Research, Hamilton, Ontario L8N 3Z5, Canada
    Am J Respir Crit Care Med 181:862-72. 2010
    ..However, the mechanisms of their maintenance on airway mucosal surface still remain poorly understood...
  37. pmc Mycobacterium tuberculosis and the host response
    Stefan H E Kaufmann
    Max Plank Institute for Infection Biology, Berlin D10117, Germany
    J Exp Med 201:1693-7. 2005
    ..tuberculosis and the infected host, the nature of protective immune responses, adaptation of the bacillus to host-imposed stresses, animal models, and new techniques...
  38. pmc CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination
    Tara Elvang
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    PLoS ONE 4:e5139. 2009
    ..tb in fact involves both CD4 and CD8 T cells. To test this, we used a new vaccine strategy that generated a strong balanced T cell response consisting of both CD4 and CD8 T cells...
  39. pmc Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis
    Nicholas P West
    Mycobacterial Research Program, Centenary Institute of Cancer Medicine and Cell Biology Locked Bag 6, Newtown, NSW 2042, Australia
    Vaccine 26:3853-9. 2008
    ..Finally, following delivery of DNA vaccines, Clp1, 2 and 6, conferred a moderate yet reproducible and significant level of protection in a murine aerosol model of M. tuberculosis infection...
  40. doi Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    APMIS 117:440-57. 2009
    ..In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies...
  41. pmc Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding
    Eung Jun Im
    Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford OX3 9DS, United Kingdom
    J Virol 81:9408-18. 2007
    ....
  42. doi Update on research and development pipeline: tuberculosis vaccines
    Belinda Beresford
    Aeras Global TB Vaccine Foundation, Rockville, Maryland 20850, USA
    Clin Infect Dis 50:S178-83. 2010
    ....
  43. ncbi Half-truths and selective memory: Interferon gamma, CD4(+) T cells and protective memory against tuberculosis
    Lisa Goldsack
    Malaghan Institute of Medical Research, P O Box 7060, Wellington South 6021, New Zealand
    Tuberculosis (Edinb) 87:465-73. 2007
    ..A comprehensive understanding of the requirements for protective memory immunity to tuberculosis is essential for the development of an effective vaccine...
  44. pmc DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy
    Andrea M Hebert
    Epidemiology Department, School of Public Health, University of Michigan, 109 S Observatory Street, Ann Arbor, MI 48109 2029, USA
    Infect Immun 75:5798-805. 2007
    ..Thus, immunity induced by Mtb72F may not recognize a proportion of M. tuberculosis clinical strains...
  45. ncbi Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein
    Yasir A W Skeiky
    Corixa Corp, Seattle, WA 98104, USA
    J Immunol 172:7618-28. 2004
    ..tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans...
  46. ncbi Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis
    Vasan K Sambandamurthy
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States
    Vaccine 24:6309-20. 2006
    ..tuberculosis. Given its overall safety and effectiveness, the mc(2)6030 live attenuated strain should be considered as a human vaccine candidate for protecting both healthy and HIV-infected individuals against TB...
  47. doi Respiratory mucosal immunization with adenovirus gene transfer vector induces helper CD4 T cell-independent protective immunity
    Jingyu Mu
    Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics and M G DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
    J Gene Med 12:693-704. 2010
    ..However, whether virus-mediated mucosal immunization can produce immune protective CD8 T cells without the CD4 T cell help remains to be investigated...
  48. doi TB vaccines: current status and future perspectives
    Claus Aagaard
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Immunol Cell Biol 87:279-86. 2009
    ..Three such fusion proteins are currently in clinical trials, the two most advanced have already passed phase I trials and are entering phase II...
  49. pmc Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
    Ansar A Pathan
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    Vaccine 30:5616-24. 2012
    ....
  50. pmc CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis
    Lian Ni Lee
    Nuffield Department of Medicine, University of Oxford, The Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, United Kingdom
    Infect Immun 79:3328-37. 2011
    ....
  51. pmc Unique model of dormant infection for tuberculosis vaccine development
    Suely S Kashino
    The Forsyth Institute, 140 The Fenway, Boston, MA, 02115 3799, USA
    Clin Vaccine Immunol 13:1014-21. 2006
    ..tuberculosis strain 18b constitutes a simple and attractive animal model for evaluation of antituberculosis vaccines in the context of an M. tuberculosis-presensitized host, a prevailing condition among humans in need of a vaccine...
  52. ncbi Tuberculosis vaccine development; from mouse to man
    Steven Reed
    Infectious Disease Research Institute, 1124 Columbia St, Ste 600, Seattle, WA 98104, USA
    Microbes Infect 7:922-31. 2005
    ..Safety, immunogenicity, and protection studies in mice, guinea pigs, rabbits, and monkeys supported the initiation of clinical development of Mtb72f in AS02A...
  53. pmc Co-administration of IL-1+IL-6+TNF-α with Mycobacterium tuberculosis infected macrophages vaccine induces better protective T cell memory than BCG
    Vijender Singh
    Immunology Laboratory, Institute of Microbial Technology, Chandigarh, India
    PLoS ONE 6:e16097. 2011
    ..tb can be utilized with great efficacy especially in protection against TB...
  54. doi Novel tuberculosis vaccines on the horizon
    Shreemanta K Parida
    Max Planck Institute for Infection Biology, Department of Immunology, Berlin, Germany
    Curr Opin Immunol 22:374-84. 2010
    ..The live mutants of Mycobacterium tuberculosis show great promise, but face a myriad of regulatory challenges...
  55. doi A comparison of IFNgamma detection methods used in tuberculosis vaccine trials
    Natalie E R Beveridge
    Jenner Institute, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK
    Tuberculosis (Edinb) 88:631-40. 2008
    ..Future tuberculosis vaccine trials and immunology studies should ideally include a combination of ex vivo and cultured assays to ensure a thorough and multifaceted evaluation of the immune response is achieved...
  56. doi Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs
    Y Liang
    Army Tuberculosis Prevention and Control Key Laboratory, Institute of Tuberculosis Research, the 309th Hospital of Chinese PLA, Beijing, China
    Scand J Immunol 74:42-6. 2011
    ..03-1.38 logs, respectively. Ag85A DNA combined with conventional chemotherapy for the treatment of MDR-TB might result in cure of MDR-TB in developing countries...
  57. doi Recombinant live vaccine candidates against tuberculosis
    Stefan H E Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Chariteplatz 1, 10117 Berlin, Germany
    Curr Opin Biotechnol 23:900-7. 2012
    ....
  58. pmc Tuberculosis vaccines: beyond bacille Calmette-Guerin
    Helen McShane
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Philos Trans R Soc Lond B Biol Sci 366:2782-9. 2011
    ..This article reviews the leading candidate vaccines in development and considers the current challenges in the field with regard to efficacy testing...
  59. doi Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice
    Maytal Bivas-Benita
    Division of Drug Delivery Technology, Leiden Amsterdam Center for Drug Research, 2300 RA Leiden, The Netherlands
    Vaccine 27:4010-7. 2009
    ..These results confirm that PLGA-PEI np are an efficient DNA vaccine delivery system to enhance T cell responses through pulmonary delivery in a DNA prime/protein boost vaccine regimen...
  60. doi Airway luminal T cells: a newcomer on the stage of TB vaccination strategies
    Mangalakumari Jeyanathan
    Centre for Gene Therapeutics, M G DeGroote Institute for Infectious Disease Research, and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, L8N 3Z5 Canada
    Trends Immunol 31:247-52. 2010
    ..tuberculosis challenge restores protection. We propose that understanding the biology of airway luminal T cells holds important implications for developing effective TB vaccination strategies...
  61. ncbi First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses
    Tom H M Ottenhoff
    Leiden University Medical Center, Dept of Infectious Diseases, Leiden, The Netherlands
    Hum Vaccin 6:1007-15. 2010
    ..These findings encourage further preclinical and clinical studies with TB subunit vaccines and cellular immunity-stimulating new adjuvants...
  62. pmc Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A
    Kristin L Griffiths
    The Jenner Institute, Oxford University, Oxford, United Kingdom
    PLoS ONE 6:e23463. 2011
    ..These results suggest a relationship between extracellular ATP and effector responses and unveil a possible pathway that could be targeted during vaccine design...
  63. doi Liposome-based cationic adjuvant formulations (CAF): past, present, and future
    Dennis Christensen
    Vaccine Delivery and Formulation, Department Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    J Liposome Res 19:2-11. 2009
    ....
  64. pmc Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system
    María Dolores Juárez-Rodríguez
    Center for Infectious Diseases and Vaccinology at Biodesign Institute, Arizona State University, Tempe, Arizona, USA
    Infect Immun 80:798-814. 2012
    ....
  65. ncbi Superexpression of tuberculosis antigens in plant leaves
    Yuri L Dorokhov
    Department of Virology and A N Belozersky Institute of Physico Chemical Biology, Moscow State University, Moscow 119992, Russia
    Tuberculosis (Edinb) 87:218-24. 2007
    ..We propose that the strategy of TB antigens superproduction in a plant might be used as a basis for the creation of prophylactic and therapeutic vaccine against TB...
  66. pmc Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis
    Michael J Brennan
    Aeras, Rockville, MD 20850, USA
    Vaccine 30:2811-23. 2012
    ....
  67. doi Clinical trials of TB vaccines: harmonization and cooperation
    Hassan Mahomed
    South African TB Vaccine Initiative, University of Cape Town, Cape Town, South Africa
    Tuberculosis (Edinb) 92:S21-4. 2012
    ..Lastly, there needs to be sufficient funding to support TB vaccine development. These challenges can be met through commitment by all role-players within the TB vaccine arena and with support from external stakeholders...
  68. ncbi DNA vaccines for therapy of tuberculosis: where are we now?
    Douglas B Lowrie
    National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK
    Vaccine 24:1983-9. 2006
    ..This review summarises the data and assesses future prospects...
  69. pmc Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines
    Ted Cohen
    Division of Global Health Equity, Brigham and Women s Hospital, Boston MA 02115, USA
    Proc Natl Acad Sci U S A 105:16302-7. 2008
    ..plays an important role in reducing the morbidity of tuberculosis (TB) infection during childhood, new tuberculosis vaccines are necessary to disrupt the transmission of disease and improve global control of this pathogen...
  70. ncbi Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis
    S J Ha
    Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science and Technology, 790 784 Pohang, Republic of Korea
    Gene Ther 12:634-8. 2005
    ....
  71. doi Tuberculosis in Africa: learning from pathogenesis for biomarker identification
    Stefan H E Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Chariteplatz 1, D 10117 Berlin, Germany
    Cell Host Microbe 4:219-28. 2008
    ..Moreover, we outline our attempts to develop biomarkers, which could help the monitoring of TB clinical trials, provide the basis for new diagnostics, and allow prognosis of outcome of infection and of drug treatment...
  72. pmc Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose
    Claus Aagaard
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    PLoS ONE 4:e5930. 2009
    ..4 delivered in the adjuvant IC31 for the ability to induce protection against infection with Mycobacterium tuberculosis. In addition, we examined if the antigen dose could influence the phenotype of the induced T cells...
  73. pmc The protective role of antibody responses during Mycobacterium tuberculosis infection
    F Abebe
    University of Oslo, Faculty of Medicine, Institute of General Practice and Community Medicine, Section for International Health, Oslo, Norway
    Clin Exp Immunol 157:235-43. 2009
    ....
  74. ncbi GLS/IL-12-modified Mycobacterium smegmatis as a novel anti-tuberculosis immunotherapeutic vaccine
    C Yang
    Department of Pathobiology, Chongqing Medical University, Chongqing, People s Republic of China
    Int J Tuberc Lung Dis 13:1360-6. 2009
    ..To study the effects and mechanisms of recombinant Mycobacterium smegmatis (rMS) carrying pZM03 (a co-expression plasmid encoding human granulysin [GLS] and murine interleukin 12 [IL-12]) on murine M. tuberculosis infection...
  75. doi The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-gamma response
    Carla Palma
    Department of Infectious, Parasitic and Immune Mediated Diseases, Istituto Superiore di Sanita, Viale Regina Elena, 299 00161 Rome, Italy
    Vaccine 26:4237-43. 2008
    ..The recovery of protection through a down-modulation of antigen-specific IFN-gamma response by an adjuvant is a novel finding which could be of relevance in tuberculosis vaccination...
  76. doi Evaluation of new vaccines for tuberculosis in the guinea pig model
    Ann Williams
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, Wiltshire, UK
    Tuberculosis (Edinb) 89:389-97. 2009
    ....
  77. ncbi DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation
    Shigeto Yoshida
    Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical School, Tochigi 329 0498, Japan
    Vaccine 24:1191-204. 2006
    ..tuberculosis. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine...
  78. pmc Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University Hospital, De Pintelaan 185, B 9000 Ghent, Belgium
    Clin Vaccine Immunol 17:1763-71. 2010
    ..In conclusion, Mtb72F/AS02(A) is clinically well tolerated and is highly immunogenic in TB-naïve adults. The 10- and 40-μg Mtb72F/AS02(A) vaccines show comparable safety and immunogenicity profiles...
  79. doi Tuberculosis: vaccines in the pipeline
    Lan H Ly
    Department of Microbial and Molecular Pathogenesis, College of Medicine, Texas A and M University System Health Science Center, College Station, TX 77843 1114, USA
    Expert Rev Vaccines 7:635-50. 2008
    ..Some of these new vaccines may eventually be recommended for travelers to TB high-burden countries. This paper summarizes the progress of vaccine candidates in animal models to improve, replace or augment BCG vaccination...
  80. pmc Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine
    Steven C Derrick
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Immunology 120:192-206. 2007
    ....
  81. ncbi Development of vaccines to control bovine tuberculosis in cattle and relationship to vaccine development for other intracellular pathogens
    Bryce M Buddle
    AgResearch, Wallaceville Animal Research Centre, P O Box 40063, Upper Hutt, New Zealand
    Int J Parasitol 33:555-66. 2003
    ..bovis genome have provided opportunities for the rational development of improved tuberculosis vaccines. A number of new tuberculosis vaccines including attenuated M...
  82. doi Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI
    C Vilaplana
    Experimental Tuberculosis Unit, Germans Trias I Pujol Health Science Research Institute Foundation, Autonomous University of Barcelona, Crtra del Canyet s n, Edifici Recerca, Catalonia, Spain
    Vaccine 28:1106-16. 2010
    ..These results support the feasibility of future evaluation, to be targeted at subjects with latent tuberculosis infection (LTBI)...
  83. doi The second Geneva Consensus: Recommendations for novel live TB vaccines
    K B Walker
    HPA NIBSC, Blanche Lane, South Mimms, Potters Bar, UK
    Vaccine 28:2259-70. 2010
    ..v. Consider requirements and associated issues related to the use of these new vaccines within an existing BCG vaccination programme...
  84. pmc rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector
    Isabelle Magalhaes
    Microbiology, Tumor and Cell Biology Center, Karolinska Institutet, Solna, Sweden
    PLoS ONE 3:e3790. 2008
    ..4, for the capacity to induce antigen-specific cellular immune responses in rhesus macaques (Macaca mulatta). Control animals received diluent (3 animals)...
  85. pmc The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection
    Ela Martin
    Centenary Institute of Cancer Medicine and Cell Biology, Newtown, NSW, Australia
    Immunology 109:308-14. 2003
    ..avium infection above that achieved by BCG, and this strategy may improve the efficacy of subunit vaccines against M. leprae and M. tuberculosis...
  86. ncbi Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, DK 2300 Copenhagen, Denmark
    J Immunol 177:6353-60. 2006
    ..tb in LTK63/Ag85B-ESAT-6-boosted mice, compared with BCG-vaccinated animals. Thus, LTK63/Ag85B-ESAT-6 represents an efficient preventive vaccine against tuberculosis with a strong ability to boost prior BCG immunity...
  87. pmc Genome plasticity of BCG and impact on vaccine efficacy
    Roland Brosch
    Unite de Genetique Moleculaire Bacterienne, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France
    Proc Natl Acad Sci U S A 104:5596-601. 2007
    ..Furthermore, the combined findings suggest that early BCG vaccines may even be superior to the later ones that are more widely used...
  88. ncbi Use of the bovine model of tuberculosis for the development of improved vaccines and diagnostics
    R G Hewinson
    TB Research Group, Department of Bacterial Diseases, VLA Weybridge, Addlestone, Surrey KT15 3NB, UK
    Tuberculosis (Edinb) 83:119-30. 2003
    ..Finally we have been able to use the model to develop a vaccine that improves the efficacy of BCG against M. bovis challenge...
  89. pmc Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules
    S S Kashino
    The Forsyth Institute, Boston, MA, USA
    Clin Exp Immunol 153:56-62. 2008
    ....
  90. ncbi Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection
    May Young Lin
    Department of Immunohaematology and Blood Transfusion, Leiden University Medical Centre, NL 2300 RC Leiden, The Netherlands
    Biol Chem 389:497-511. 2008
    ..tuberculosis infection. We will discuss the possible relevance of these new classes of antigens for vaccine development against TB...
  91. pmc Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis
    Steven G Smith
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS ONE 4:e7972. 2009
    ..A pre-stimulation step may improve the sensitivity of the assay, particularly when cells have been previously frozen...
  92. doi Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis
    Carine Rouanet
    INSERM U629, F 59019 Lille, France
    Microbes Infect 11:995-1001. 2009
    ..7log when compared to BCG alone. These results suggest an immunisation strategy where BCG is administered to neonates and is followed by subcutaneous HBHA boosting in young adults...
  93. ncbi Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis
    L D Aguilar
    Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Vasco de Quiroga 15, Tlalpan, Mexico City CP 14000, Mexico
    Vaccine 24:2333-42. 2006
    ....
  94. ncbi Tuberculosis vaccines - an update
    Peter Andersen
    Nat Rev Microbiol 5:484-7. 2007
  95. pmc Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain
    D Aguilar
    Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico
    Clin Exp Immunol 147:330-8. 2007
    ..The levels of protection conferred by vaccination with M. tuberculosis SO2 or with M. bovis BCG were similar, as measured by granuloma coalescence and pneumonia in addition to growth reduction of M. tuberculosis H37Rv...
  96. ncbi Current status of TB vaccines
    Umesh Datta Gupta
    National JALMA Institute for Leprosy and Other Mycobacterial Disease ICMR, P Box No 1101, Tajganj, Agra 282001, India
    Vaccine 25:3742-51. 2007
    ..These recent advances in the clinical testing of new TB vaccines are very exciting and promising. However, there is a need to continue the search for additional vaccine candidates or vaccination strategies...
  97. ncbi Prime-boost immunisation strategies for tuberculosis
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Microbes Infect 7:962-7. 2005
    ..Using BCG as the priming immunisation in such a heterologous prime-boost strategy is a practical solution, which allows the beneficial effects of BCG in children to be maintained...
  98. pmc Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A
    Kathryn T Whelan
    Jenner Institute, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 4:e5934. 2009
    ....
  99. ncbi Immunology of tuberculosis and implications in vaccine development
    JoAnne L Flynn
    Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, W1157 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Tuberculosis (Edinb) 84:93-101. 2004
    ..Studying both the host and the pathogen will elucidate potential vaccine candidates. In this review, the known functions of immune components in the response to M. tuberculosis and implications for vaccine development will be discussed...
  100. ncbi Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates
    Carlos Franco-Paredes
    Hospital Infantil de Mexico Federico Gomez, Mexico
    Int J Infect Dis 10:93-102. 2006
    ..New vaccine candidates may offer better protection than that afforded by currently available BCG vaccines. Furthermore, combined vaccination schedules against TB seem to be a promising strategy in the new millennium...
  101. ncbi The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans
    Kenneth von Eschen
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Hum Vaccin 5:475-82. 2009
    ..This first trial in humans found Mtb72F/AS02A to have an acceptable tolerability, to be immunogenic in healthy adults and warrants further development of the vaccine...

Research Grants78

  1. MYCOBACTERIAL GENES ANTIGENS AND VACCINES
    Barry Bloom; Fiscal Year: 2000
    ..in this competitive renewal application, they propose to develop effective and safe live attenuated tuberculosis vaccines by generating defined mutations in the M...
  2. DIETARY DEFICIENCIES AND TUBERCULOSIS VACCINE EFFICIENCY
    David McMurray; Fiscal Year: 2004
    ..New tuberculosis vaccines will be tested, ultimately, in malnourished humans...
  3. Mechanisms of Mycobacterial Antigen Processing
    Chinnaswamy Jagannath; Fiscal Year: 2010
    ..William Hildebrand). The teams will perform vaccine evaluation, genetic re-construction and epitope discovery in a highly synergistic manner and boost our existing knowledge on anti-tuberculosis vaccines.
  4. Mechanisms of Mycobacterial Antigen Processing
    Chinnaswamy Jagannath; Fiscal Year: 2009
    ..William Hildebrand). The teams will perform vaccine evaluation, genetic re-construction and epitope discovery in a highly synergistic manner and boost our existing knowledge on anti-tuberculosis vaccines.
  5. Mechanisms of Immune Regulation in Mycobacterium Tuberculosis Infection
    CHERYL LIANE DAY; Fiscal Year: 2010
    ..fails in some infected individuals who progress to develop active tuberculosis disease;such studies will open up new avenues of research on immunotherapeutic interventions and the design of more effective tuberculosis vaccines.
  6. Mechanisms of Immune Regulation in Mycobacterium Tuberculosis Infection
    Cheryl Day; Fiscal Year: 2009
    ..fails in some infected individuals who progress to develop active tuberculosis disease; such studies will open up new avenues of research on immunotherapeutic interventions and the design of more effective tuberculosis vaccines.
  7. POPULATION-BASED MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS
    Philip Hopewell; Fiscal Year: 2000
    ..5) To use information from the study sites to develop approaches to the evaluation of candidate tuberculosis vaccines. Taken together this group of aims will serve to provide the epidemiologic basis for tuberculosis control ..
  8. LATENCY AND REACTIVATION TUBERCULOSIS
    William Bishai; Fiscal Year: 2002
    ..Appropriate animal models are critical to the successful development of tuberculosis vaccines, new drugs and better diagnostic tests for tuberculosis.
  9. LATENCY AND REACTIVATION TUBERCULOSIS
    YUKARI MANABE; Fiscal Year: 2006
    ..Appropriate animal models are critical to the successful development of tuberculosis vaccines, new drugs and better diagnostic tests for tuberculosis.
  10. Heat Shock Protein based vaccine for Tuberculosis
    ANNIE MO; Fiscal Year: 2003
    ..heat shock protein-peptide complexes to elicit T cell responses may address a shortcoming of traditional tuberculosis vaccines that primarily elicit antibody responses...
  11. Response Therapies for MDR-TB
    Ian Orme; Fiscal Year: 2007
    ..Safety testing issues, toxicology testing, and process development leading to GMP production are also planned for the later stages of this proposed program. ..
  12. STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE
    Ian Orme; Fiscal Year: 2004
    ..abstract_text> ..
  13. CHRONIC TUBERCULOSIS--LATENT OR DYNAMIC
    Ian Orme; Fiscal Year: 2003
    ..In this latter endeavor we shall be assisted by highly qualified mycobacterial chemists from within the Mycobacteria Research Laboratories [MRL] at CSU. ..
  14. Chronic Tuberculosis: Latent or Dynamic
    Ian Orme; Fiscal Year: 2007
    ....
  15. Guinea pig model for TB vaccine evaluations
    Ian Orme; Fiscal Year: 2007
    ..of infected guinea pigs, The proposed studies are lengthy, and unavoidably expensive, but should provide a basic framework upon which a standardized procedure for efficacy and safety testing of new tuberculosis vaccines can be based.
  16. DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 2006
    ..The proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories at Colorado State University, as well as several eminent consultants and advisers. ..
  17. AGING AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 1993
    ..Using data gathered by these diverse procedures, it is anticipated that new important knowledge will be gained regarding the precise events which occur in the aged animal exposed to virulent pulmonary tuberculosis...
  18. DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 2000
    ..As previously in this Program, the proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories, CSU, as well as a number of highly qualified consultants/collaborators. ..
  19. AGING AND IMMUNITY IN TUBERCULOSIS
    Ian Orme; Fiscal Year: 2002
    ....
  20. GENE EXPRESSION OF M.TUBERCULOSIS WITHIN MACROPHAGES
    Kathleen McDonough; Fiscal Year: 2004
    ..This work will contribute to our understanding of the factors needed for the establishment of tuberculosis infection and disease and will identify potential targets for tuberculosis vaccines, therapeutics, and diagnostic purposes.
  21. Role of DAP12 in type 1 anti-mycobacterial immunity
    Zhou Xing; Fiscal Year: 2005
    ..We strongly believe that our studies will provide new insights into the mechanisms of type 1 anti-microbial immunity and novel targets for immune modulation. ..
  22. Human T Cell Antigens of Mycobacterium tuberculosis
    Steven Reed; Fiscal Year: 2009
    ..Finally, we will test antigens/vaccine formulations in rodent models of infection and disease. By the end of the funding period, we will have defined a second vaccine candidate for entry into clinical trials. ..
  23. Development & Manufacture of an MDR Tuberculosis Vaccine
    Steven Reed; Fiscal Year: 2005
    ..This will enable us to immediately proceed to human clinical trials after the end of the funding period. ..